# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
As the popularity of GLP-1 receptor agonists continues to surge in the treatment of obesity and type 2 diabetes, Evofem Bioscie...
This amended and restated Merger Agreement, among others, addresses pre-closing issues critical for Evofem's future success...
-8-K
https://www.washingtonpost.com/world/2024/03/04/france-abortion-constitution/
Laidlaw & Co. analyst Yale Jen downgrades Evofem Biosciences (OTC:EVFM) from Buy to Hold.
Aditxt Inc (NASDAQ: ADTX) has agreed to acquire Evofem Biosciences Inc (OTC: EVFM) in consideration of the issuance of a combin...
Evofem posted $13.4 million in net sales of Phexxifor the first nine months of 2023;Aditxt looks to accelerate Evofem into the ...
-- Padagis Determined They Will Not Challenge the Phexxi Patents -- -- Evofem Has Phexxi Patent Protection Through 2033 --